Raziel Announces China Market License Agreement with Fosun Pharma for RZL 012

REHOVOT, Israel, Sept. 17, 2020 /PRNewswire/ -- Raziel Therapeutics, a Pharmaceutical company developing next-generation novel prescription products for the medical aesthetics market announces licensing of its disruptive technology, RZL-012, to Fosun Pharma for milestone payments of up to $74 million, based on development, regulatory and net sales achievements plus tiered royalties on future sales. Click here to read more

Raziel Announces China Market License Agreement with Fosun Pharma for RZL 012

REHOVOT, Israel, Sept. 17, 2020 /PRNewswire/ -- Raziel Therapeutics, a Pharmaceutical company developing next-generation novel prescription products for the medical aesthetics market announces licensing of its disruptive technology, RZL-012, to Fosun Pharma for milestone payments of up to $74 million, based on development, regulatory and net sales achievements plus tiered royalties on future sales. Click here to read more

Recent Posts
Featured Posts
Archive
Search By Tags

Contact Info

6 Yoni Netanyahu Street
Or Yehuda, 60376, Israel

Phone: +972 -3- 634 9990 
Fax: +972 -3- 634 9910

 

Map & Directions >>

Portfolio

Life Sciences

Software

 

 

© Peregrine Ventures  |  Terms & Conditions  |  Privacy Policy